Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.81 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | IDH1 | O75874 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968245 | 1.00 | HSD11B1 (0.81) | HSD11B1PDE4AHSD17B3PDE4BPDE4C | |
| SCHEMBL1969210 | 0.90 | HSD11B1 (1.00) | HSD11B1IDH1 | |
| SCHEMBL1969737 | 0.90 | HSD11B1 (1.00) | HSD11B1IDH1 | |
| SCHEMBL1969736 | 0.90 | HSD11B1 (1.00) | HSD11B1IDH1 | |
| SCHEMBL2004913 | 0.88 | HSD11B1 (0.86) | HSD11B1IDH1 | |
| SCHEMBL1967790 | 0.88 | HSD11B1 (0.86) | HSD11B1IDH1 | |
| SCHEMBL3266372 | 0.88 | HSD11B1 (0.86) | HSD11B1IDH1 | |
| SCHEMBL4451259 | 0.88 | HSD11B1 (0.86) | HSD11B1IDH1 | |
| SCHEMBL13182710 | 0.87 | HSD11B1 (0.63) | HSD11B1PDE4AHSD17B3PDE4BPDE4C | |
| SCHEMBL3245326 | 0.86 | HSD11B1 (1.00) | HSD11B1PDE4AHSD17B3PDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086939-B8 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2011-06-22 | — | — | EP | claimed |
| EP-2086939-A2 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | AstraZeneca AB (SE) | 2009-08-12 | — | — | EP | claimed |
| WO-2008053194-A2 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | claimed |
| US-7964618-B2 | 2-[(3R)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid, for example; compounds possess human 11- beta-hydroxysteroid dehydrogenase type1 enzyme (11 beta HSD1) inhibitory activity and accordingly have value in treatment of disease states including metabolic syndrome | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269288-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | HSD11B1 1/4885PDE4A 436/4885HSD17B3 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.